Capstone Therapeutics Announces Completion of Enrollment for Second of Two AZX100 Phase 2 Studies in Keloid Scarring; Phase 2 Study in Shoulder Surgery Scarring Reaches Enrollment Milestone

TEMPE, Ariz., Sept. 30, 2009 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) announced today the completion of enrollment for the second of its two ongoing AZX100 Phase 2 clinical trials in keloid scarring. The company also announced that its AZX100 Phase 2 clinical trial in trocar site scarring due to arthroscopic shoulder surgery has reached an enrollment milestone to accommodate a limited interim analysis for internal review by mid-year 2010.